Podcasts about psychedelic research group

In recent years there's been a renaissance of interest in psychedelics in the West, on a scale not seen since the first wave of medical research in the 1950s and 60s. Drugs like DMT, ketamine and psilocybin (that's the psychoactive compound in magic mushrooms), are now being researched as medications to take alongside therapy for the treatment of various mental health problems. Across this series of interviews, Rose Cartwright explores so-called ‘psychedelic assisted psychotherapy'. What is it? Can it help tackle our mental health crisis? And what are the risks?Her first guest is clinical psychologist Ashleigh Murphy-Beiner from the Psychedelic Research Group at Imperial College, which is working on medical trials with psilocybin and MDMA for the treatment of depression and complex trauma. What is complex trauma and how might psychedelic drugs help to make sense of it? What can we learn from indigenous healers when trialling these drugs within a western clinical framework? And how could psychedelic-assisted therapy play out within the NHS if these drugs become legalised for medical use? Producer: Becky Ripley

The Harvard Psychedelics Project at Harvard Divinity School, a student organization, presented this conference to gather faculty, researchers, and students from across Harvard University to explore their diverse, interdisciplinary, and promising research on psychedelics. Speakers came from across the University's Schools, units, and departments, including the Dana Farber Cancer Institute, Harvard Business School, Harvard College, Harvard Divinity School, Harvard Graduate School of Arts and Sciences, Harvard Graduate School of Education, Harvard Law School, Harvard Medical School, Massachusetts General Hospital, and POPLAR at the Petrie-Flom Center. This third series of talks featured Suzannah Clark, Max Ingersoll, Logan Fahrenkopf, Jeffrey Breau, and Paul Gillis-Smith. This event took place on April 1, 2023 Learn more: https://cswr.hds.harvard.edu/

The Harvard Psychedelics Project at Harvard Divinity School, a student organization, presented this conference to gather faculty, researchers, and students from across Harvard University to explore their diverse, interdisciplinary, and promising research on psychedelics. Speakers came from across the University's Schools, units, and departments, including the Dana Farber Cancer Institute, Harvard Business School, Harvard College, Harvard Divinity School, Harvard Graduate School of Arts and Sciences, Harvard Graduate School of Education, Harvard Law School, Harvard Medical School, Massachusetts General Hospital, and POPLAR at the Petrie-Flom Center. This first series of talks featured Franklin King, Yvan Beaussant, Grant Jones, Fernando Espi Forcen, Stephen J. Haggarty, Jeffrey Breau, and Paul Gillis-Smith. This event took place on April 1, 2023 Learn more: https://cswr.hds.harvard.edu/

The Harvard Psychedelics Project at Harvard Divinity School, a student organization, presented this conference to gather faculty, researchers, and students from across Harvard University to explore their diverse, interdisciplinary, and promising research on psychedelics. Speakers came from across the University's Schools, units, and departments, including the Dana Farber Cancer Institute, Harvard Business School, Harvard College, Harvard Divinity School, Harvard Graduate School of Arts and Sciences, Harvard Graduate School of Education, Harvard Law School, Harvard Medical School, Massachusetts General Hospital, and POPLAR at the Petrie-Flom Center. This first series of talks featured Charles Stang, Natalia Schwien, Rachael Petersen, Andrea Lerner, Ned Hall, Justin Williams, Jeffrey Breau, and Paul Gillis-Smith. This event took place on April 1, 2023 Learn more: https://cswr.hds.harvard.edu/

Sam Gandy is an ecologist, writer and researcher with a PhD in ecological science from the University of Aberdeen and an MRes in entomology from Imperial College London. He has been involved with the cutting edge of psychedelic research, working as Scientific Assistant to the Director of the Beckley Foundation, and as a collaborator with the Psychedelic Research Group at Imperial College London. Sam is also an innovation leader with Ecosulis, offering nature-based solutions and accelerating local and global rewilding projects. This conversation spans easing existential anxiety, psilocybin-assisted therapy and the hopeful reintroduction of beavers across Britain. Could social projects of regeneration be married to psychedelic-assisted therapy? What other ways can we innovate more nature connection and regeneration, whilst also healing our inner and outer landscapes?Join our Patreon community for exclusive offerings from our podcast guests.Visit Rooted Healing to learn more about our work and sign up for our newsletter.Thank you to Mike Howe for his ongoing music contributions.

Can psychedelic therapy help depression? We are now in the middle of the first psychedelic resurgence since the last bout of research in the 60's and 70's led by legends of the psychedelic movement like Dr. Stan Grof at Harvard. This resurgence is taking place on two fronts: Firstly, following promising results from Imperial College's Psidep 1 study into the use of Psilocybin, the active ingredient in Magic Mushrooms, to treat treatment-resistant depression; there has been a host of studies around the world at leading universities like Harvard investigating many other compounds as well as Psilocybin like famous rave drug MDMA and horse tranquilliser Ketamine. This is an odd turn of events for compounds that have been systematically demonised by governments and accused of worsening mental health conditions. Secondly, we are seeing a a massive increase in the participation of Ahyuasca rituals, whose active ingredient is DMT, one of the most hallucinogenic compounds in the world, to the point that it has become a fashion among the funky philosophical Burning Man style community. The world of medicine and personal transformation seem to be converging. But we need a specialist to clarify the details here before we get ahead of ourselves. So who better to help us navigate this new territory than assistant psychologist on Imperial's most recent psilocybin study, Ashleigh Murphy Beiner. Ashleigh Murphy-Beiner is a Trainee Clinical Psychologist and Mindfulness Practitioner. She is a member of the Psychedelic Research Group at Imperial College London. She is also a scientific researcher and has published research investigating the therapeutic use of ayahuasca. Her research has found changes in mindfulness and cognitive flexibility after ayahuasca use which both play a role in psychological wellbeing. What we discuss: 00:00 Inequality and suffering and how to deal with that experience 05:20 Victor Frankel and thriving from the fundamental quest for human meaning 07:49 Treatment resistant depression, ruminating about the past and social disconnection 14:00 Psychedelics reduce rumination (DMN) and increase plasticity 16:00 Mazatec and North American Indian traditions of healing using hallucinogens 17:30 Plants have their own agency in the indigenous worldview 18:30 Imperial Colleges 2nd Psilocybin Study for depression explained 28:00 The results and how they compared to Psidep1, the first study 31:00 No magic answer to long-term effectiveness challenges against Depression 33:00 ‘Restoring a quality of life' despite persistent depression symptoms 34:12 Dr. Rosalind Watts' ACE (Accept, Connect, Embody) Model of treatment and post traumatic growth 36:30 Avoidance to acceptance, and disconnection from others, themselves and the world to connection to those things 39:00 Embody: allowing yourself to feel the pain 43:30 Yohann Hari and the wider systemic issues of inequality leading to depression 45:30 How it feels to publish your first scientific paper 46:00 Ashleigh's study of Ahyuasca's effects on cognition 49:00 The commercialisation of Ahyuasca and reciprocity 53:00 Common threads of between Ahyuasca, NDE and psilocybin experiences 56:20 The value of studying altered states of consciousness 1:00:00 Evidence that trauma is stored in the body References: Victor Frankel Dr. Gabor Mate documentary Yohann Hari book 'Lost Connections'

Dr. Paul Liknaitzky and I both work (okay, I study) in the same building at Monash University and are both part of the School of Psychological Sciences but that's where the similarities end. Unlike me, Paul is an actual academic doing ground-breaking research, while I'm fumbling my way through my second year of PhD student life (thanks to the awesome team at @brainparkmonash). Paul is head of the Psychedelic Research Group at Monash, Chief Principal Investigator, Research Fellow and has Adjunct or Honorary appointments at St Vincent's Hospital, Macquarie University, Deakin University, and the University of Melbourne. He's also Principal Investigator across a number of Australia's first clinical psychedelic trials. Paul is currently establishing a rigorous program of research in psychedelic medicine at Monash that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks and understand therapeutic mechanisms. This was a fascinating episode, he's a fascinating bloke and I loved our chat. Enjoy. *FYI.. BrainPark (where I'm based) is a world-first neuroscience research clinic dedicated to creating better outcomes for people with compulsive behaviours; from unhealthy habits through to addictions and obsessive-compulsive disorder.@PLiknaitzky

Robin Heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College London, where he has designed several functional brain imaging studies with psilocybin, LSD, MDMA  and DMT, plus a clinical trial of psilocybin for treatment resistant depression. He has over 50 published papers in peer-reviewed scientific journals; two of which were ranked in the top 100 most impactful academic articles of 2016. Robin's research has featured in major national and international media and he has given a popular TEDx talk.Does MDMA impact sleep?What does the brain look like under the influence of LSD?How do psychedelics change the quality of brain activity? Can psilocybin be used to treat depression? Psilocybin vs Escitalopram for Major Depressive Disorder  Stanislav Grof LSD PsychotherapyRobin's first paper – Waves of the Unconscious Amanda FeildingRobin's PhD Drugs live – Channel 4Psilocybin LSD MDMADMTPsychedelic resting states The entropic brainHomological scaffolds of brain functional networksThe Stoned Ape theory DMT Neural Correlates of the DMT experience Psilocybin for Treatment-Resistant Depression Serotonin and brain function: a tale of two receptors ★ Support this podcast ★

I talk to Robin Carhart Harris about an important tool of the future: psychedelics. Robin has the aura of your typical “cool scientist” and heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College London. He has designed a number of functional brain imaging studies with psilocybin, LSD, MDMA and DMT, plus a clinical trial of psilocybin for treatment resistant depression. Carhart-Harris is the first person in the UK to have legally administered doses of LSD to human volunteers since the Misuse of Drugs Act of 1971. He is passionate about finding proof, that we need new mental health drugs.

Christopher Timmermann currently works at the Psychedelic Research Group in Imperial College London. He is currently leading a study involving the effects of DMT in the human brain and experience.  Studying transitions in and out of the altered state of consciousness caused by intravenous (IV) N,N-Dimethyltryptamine (DMT - a fast-acting tryptamine psychedelic) offers a safe and powerful means of advancing knowledge on the neurobiology of conscious states. The research group investigates the effects of IV DMT on the power spectrum and signal diversity of human brain activity (6 female, 7 male) recorded via multivariate EEG, and plot relationships between subjective experience, brain activity and drug plasma concentrations across time. Compared with placebo, DMT markedly reduced oscillatory power in the alpha and beta bands and robustly increased spontaneous signal diversity. Time-referenced and neurophenomenological analyses revealed close relationships between changes in various aspects of subjective experience and changes in brain activity. Importantly, the emergence of oscillatory activity within the delta and theta frequency bands was found to correlate with the peak of the experience - particularly its eyes-closed visual component. These findings highlight marked changes in oscillatory activity and signal diversity with DMT that parallel broad and specific components of the subjective experience, thus advancing our understanding of the neurobiological underpinnings of immersive states of consciousness. (text from article link below) LINKS to Articles-  https://www.researchgate.net/publication/337342080_Neural_correlates_of_the_DMT_experience_assessed_with_multivariate_EEG https://www.researchgate.net/publication/327035360_DMT_Models_the_Near-Death_Experience https://www.imperial.ac.uk/brain-sciences/ LINKS- DMTx- www.dmtx.org  DMTx Training- https://psychedelicstoday.teachable.com/p/dmtx-psychonaut-training-webinar Book by Blake C. Erickson:  The Forbidden Fruit & The Tree of Knowledge: Opening the Third Eye- www.amazon.com/Forbidden-Fruit-Tree-Knowledge/dp/0557019524/ Music by ZencesTry on Spotify, iTunes, or visit- www.soundcloud.com/zencestry  Podcast Logo Art by Zachary Brown (Visonary Voyager)- https://www.instagram.com/visionaryvoyager/?hl=en Patreon support for The DMT Xperience Podcast- www.patreon.com/dmtxp

Robin Heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College London, where he has designed a number of functional brain imaging studies with psilocybin (magic mushrooms), LSD, MDMA (ecstasy) and DMT (ayahuasca), plus a clinical trial of psilocybin for treatment resistant depression. He has over 50 published papers in peer-reviewed scientific journals; two of which were ranked in the top 100 most impactful academic articles of 2016. Robin’s research has featured in major national and international media and he has given a popular TEDx talk.Dr Carhart-Harris moved to Imperial College London in 2009 after obtaining his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University.  In 2015 he founded the Psychedelic Research Group at Imperial, which he runs. He has an honorary position at the University of Oxford. imperial.ac.uk/people/r.carhart-harris@RCarhartHarriseastforest.org

This week, Shane interviews nine Psychedelic Scholars and Enthusiasts recorded live from the Psychedelic Symposium at The University of Michigan. They discuss Psychedelic Therapy, DMT, Consciousness and Neuroscience.  The views expressed do not necessarily reflect the views of The University of Michigan.  Psychedelic Therapy and History Rick Doblin, PhD Executive Director Multidisciplinary Association for Psychedelic Studies (MAPS) Chair of the Board of Directors  MAPS Public Benefit Corporation Alan K. Davis, PhD Licensed Psychologist and Assistant Professor College of Social Work, The Ohio State University Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University Nick Denomme, PhD Candidate Department of Pharmacology, Center for Consciousness Science, University of Michigan  DMT and Consciousness Chris Timmermann, PhD Candidate Centre for Psychedelic Research Group, Imperial College London Jon Dean, PhD Candidate Department of Molecular and Integrative Physiology, Center for Consciousness Science, University of Michigan  Nick Glynos, PhD Candidate Department of Molecular and Integrative Physiology, Center for Consciousness Science, University of Michigan  Psychedelic Neuroscience: Salvia, Ketamine, LSD Katrin Preller, PhD University of Zurich  Yale University Michael Brito, PhD Candidate Department of Neuroscience, Center for Consciousness Science University of Michigan  Emma Trammel, PhD Candidate Department of Neuroscience, Center for Consciousness Science University of Michigan Please visit our sponsors The Great Courses www.thegreatcoursesplus.com/hereweare  Libro.fm is the first audiobook company to make it possible for you to buy audiobooks directly through your local bookstore. Offer code: hereweare for 3 months for the price of one. https://libro.fm/redeem/HEREWEARE  I look forward to editing more awesome episodes in 2020. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, Shane interviews nine Psychedelic Scholars and Enthusiasts recorded live from the Psychedelic Symposium at The University of Michigan. They discuss Psychedelic Therapy, DMT, Consciousness and Neuroscience.  The views expressed do not necessarily reflect the views of The University of Michigan.  Psychedelic Therapy and History Rick Doblin, PhD Executive Director Multidisciplinary Association for Psychedelic Studies (MAPS) Chair of the Board of Directors  MAPS Public Benefit Corporation Alan K. Davis, PhD Licensed Psychologist and Assistant Professor College of Social Work, The Ohio State University Center for Psychedelic and Consciousness Research, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University Nick Denomme, PhD Candidate Department of Pharmacology, Center for Consciousness Science, University of Michigan  DMT and Consciousness Chris Timmermann, PhD Candidate Centre for Psychedelic Research Group, Imperial College London Jon Dean, PhD Candidate Department of Molecular and Integrative Physiology, Center for Consciousness Science, University of Michigan  Nick Glynos, PhD Candidate Department of Molecular and Integrative Physiology, Center for Consciousness Science, University of Michigan  Psychedelic Neuroscience: Salvia, Ketamine, LSD Katrin Preller, PhD University of Zurich  Yale University Michael Brito, PhD Candidate Department of Neuroscience, Center for Consciousness Science University of Michigan  Emma Trammel, PhD Candidate Department of Neuroscience, Center for Consciousness Science University of Michigan Please visit our sponsors The Great Courses www.thegreatcoursesplus.com/hereweare  Libro.fm is the first audiobook company to make it possible for you to buy audiobooks directly through your local bookstore. Offer code: hereweare for 3 months for the price of one. https://libro.fm/redeem/HEREWEARE  I look forward to editing more awesome episodes in 2020. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Rosalind Watts is a clinical psychologist at the Psychedelic Research Group at Imperial College London. The Psychedelic Research Group focuses on two main areas: psychedelic drugs in the brain and second, their clinical utility, psychotherapy, with a particular focus on depression. Support the podcast: Via our Patreon page - https://www.patreon.com/Ascend Show Notes - http://ascendbodymind.com/ascend-podcast/ Donate - https://www.paypal.me/ascendpodcast

Psychedelics have an ancient and more recent history of medicinal-use. Administered in a supportive environment, with preparatory and integrative psychological care, psychedelic medicines are now being used to facilitate emotional breakthrough and renewed perspective. Indeed, a growing body of research is indicating that these medicines, when provided with accompanying psychological support, can be used safely to treat a range of psychiatric conditions, such as end-of-life anxiety and depression, alcohol and tobacco addiction, obsessive compulsive disorder, and most recently, treatment-resistant major depression. This talk, from Robin Carhart-Harris, PhD, will detail his latest fascinating research on psilocybin for depression, as well as the results of his brain imaging work with other psychedelics. Dr Robin Carhart-Harris heads the Psychedelic Research Group at Imperial College London, where he moved to in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, he has conducted and overseen human brain imaging studies of the effects of LSD, psilocybin (magic mushrooms), MDMA and DMT (ayahuasca), plus a clinical trial of psilocybin for treatment-resistant depression. As of November 2018, he will be Associate Professor at the University of Oxford, where he will lead a new Centre for Psychedelic Research. Three of his papers ranked within the top 100 most impactful scientific papers of the year, over the last two years. His work has been featured in the Independent, New Scientist and Wired magazine. Links: Get our latest psychology lectures emailed to your inbox: http://bit.ly/new-talks Want to gift a Weekend University experience to someone else? Check out our gift vouchers: http://bit.ly/twu-vouchers Check out our next event: http://theweekenduniversity.com/events/ Support this channel on Patreon: https://www.patreon.com/theweekenduniversity Robin's research centre: https://www.imperial.ac.uk/psychedelic-research-centre Follow Robin on twitter: @RCarhartHarris

Download In this episode, Kyle joins in conversation with Dr. Sam Gandy. During the show, they cover topics including the implications psychedelics have for human well-being and the biosphere at large at a time of growing disconnection. 3 Key Points: There have been a lot of recent threats to our planet and its survival if we continue on our current path of unsustainability. Feeling connected to nature increases the human desire to take care of and heal nature. There has been an inverse correlation with our connectedness to nature and our connection with technology. Getting out in nature, as well as using psychedelics in nature, both help increase our connectedness to nature. There has been a rise in cutting edge research that reveals the capacity of psychedelic substances to enhance human-nature connection, which Sam shares snippets of throughout the episode. Support the show Patreon Leave us a review on iTunes Share us with your friends – favorite podcast, etc Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics Trip Journal                                                Integration Workbook Show Notes About Sam Sam has a PhD in Ecological Science from the University of Aberdeen and a Masters in Entomology from Imperial College London He has a lifelong interest in nature and wildlife and has conducted research in areas all over the world He is a Scientific Assistant to the Director at the Beckley Foundation He is a collaborator with the Psychedelic Research Group at the Imperial College of London Sam’s interest in psychedelics began in London when it was legal to buy mushrooms He was ‘anti-drug’ until he discovered psychedelics and began to explore consciousness and a love for nature His background in Ecology (the science of interconnection) has combined with the Psychedelic field Sam is interested in the capacity of psychedelics to increase human-nature connection and relatedness Saving Earth There is a huge threat that our planet won't survive past this century if we continue on our path of destruction Remedying our nature disconnect is something really important if we want to survive This nature disconnection is inversely proportional from our technological connection We cant live without nature We have to make room for all the other life going on, not just the life that directly serves humans, like crops and livestock There is an increasing awareness of the need for nature connection Sam mentions about humanity’s screen addiction, it raises our cortisol levels and there are many consequences such as psychological and physiological effects “Contentment is the enemy of invention” Psychedelics and the internet are growing alongside each other Timothy Leary would say the internet is the psychedelics of the future in terms of connection The internet is playing a pivotal role in access to information in this psychedelic renaissance “Technology is not good or bad, it's about how its used, the intent behind it” - Sam Nature Disconnect Sam thinks that the first step that took us away from nature is when we started farming, we became less hunter-gatherer minded and stepped away from the wild environment At that point we started living in large groups (creating cities) Then there was the division of labor and urbanization Cities and technology are the main reasons for our disconnect with nature “Long term sustainability would be one of the chief governing principles of how things are ran” - Sam Psychedelics and Nature There is something radical about psychedelics, they can convert the skeptics into appreciating nature The ego dissolution character of psychedelics are a key component in feeling connected to nature The default mode network (where the ego resides) becomes relaxed and dissolved, and when that happens there is a breakdown of perceived boundaries between self and others/nature That dissolution of boundaries is a key component in the psychedelic experience “When you feel part of it, it changes fundamentally how you relate to it” - Sam One's knowledge of nature is a very weak predictor of one's concern for nature There isn't research of the use of psychedelics in natural settings yet, Sam hopes that as we research psychedelics more (in clinical settings) the research can evolve into studying their use in nature With psilocybin, most people have claimed to have a long-term fleeting change in their connectedness to nature, that the feeling of connection doesn't go away after the trip is over, it lasts for weeks, months, even the rest of their life Rigid Egos and Nature Disconnection Psilocybin decreases blood flow to the default mode network "When we are destroying our own homes (our bodies and nature) are we falling out of love with our self?" - Kyle When we dissolve the ego, we increase connection, to ourselves, to others and to nature Future in Psychedelics We are going to see the rise of Psychedelic Therapy We are going to see Psychedelic groups and communities on the rise From those groups, we will see projects and initiatives develop, which could bring decriminalization, integration circles, etc. Sam believes the rise of depression and anxiety are a cause of our disconnection to nature, and he believes there is a lot of personal healing to be had if we get back into nature and actually play a role in healing nature too Instead of trying to save the world just for our children and our children's children, we need to look at this planet as if we were to reincarnate and come back to this planet, so we should want to look after this physical plane to make it better for future installments of ourselves Get Connected with Nature The direct, physical sensory experience with nature alone is well known to increase our connectedness with it Sam suggest listeners to get out in nature and do anything! Boating, gardening, bee keeping, a walk in the woods, whatever Sam really likes the art of Japanese Forest Bathing, which is about mindfulness and taking in nature, maybe combining it with breathwork exercises, etc. The more mindful you feel, the more connected to nature you are, and vice versa Final Thoughts Nature connection is just a single facet of the psychedelic experience, and Sam hopes for more research on this facet in the future We have a decent amount of research on psychedelics effect on people with depression, PTSD, etc, but Sam hints toward some future research on the effects of psychedelics on the healthy-normal population Make time for nature in whatever way works for you 2 hours of nature time a week are profoundly beneficial for health Links Facebook Twitter Email: greensam2512@hotmail.com About Dr. Sam Gandy Dr. Sam Gandy works on the cutting edge of psychedelic research, as Scientific Assistant to the Director of the Beckley Foundation, and as a collaborator with the Psychedelic Research Group at Imperial College London. Sam has a lifelong love of nature and wildlife, and a PhD in ecological science from the University of Aberdeen. He has been fortunate enough to conduct field research in various parts of the world including the UK, Kefalonia, Almeria, Texas, the Peruvian Amazon, Vietnam and Ethiopia. Outside his work in the psychedelic field he has written papers, book chapters, articles and spoken at conferences and festivals on psychedelics and he is fascinated by their potential to benefit human lives.

Download In this episode, Kyle interviews Dr. Alexander Belser, a Clinical Researcher who has done a variety of works in the psychotherapy and psychedelic fields, helping patients heal from depression, OCD, suicide, and other illnesses, all while focusing on gender neutrality and equality. In this episode, they cover topics on privilege, inclusivity and recommendations for the psychedelic space. 3 Key Points: Privilege is commonly seen in therapist roles and as well in an individual’s access to treatment. It's important for the psychedelic community to be vocal about privilege and be inclusive of all types of people, all repressed groups. Psychedelics have the power to help people come to terms with their own sexuality, as well as become accepting of other individuals sexual identification. In order to see more equality in the psychedelic space, we need to confront structural heterosexism and transfobia, retire the male/female therapy diad, and develop acknowledgement in the psychedelic world of the stresses that LGBTQ people face. Support the show Patreon Leave us a review on iTunes Share us with your friends – favorite podcast, etc Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics Trip Journal                                               Integration Workbook Show Notes About Alexander Alexander started attending psychedelic conferences in college He works at Yale currently, treating individuals with major depressive disorders with psilocybin assisted psychotherapy He lives in New York and works on a team for the MAPS, MDMA trial for the treatment of PTSD Queering Psychedelics Queering Psychedelics is a Conference put on with the help of Chacruna Its an opportunity for Queer folk to come together and talk about psychedelic medicine Alexander's presentation was on Queer Critique for the Psychedelic Mystical Experience Privilege and Inclusivity People with more privilege have more power, more access to funding, more access to expanding the research agenda Many of the people in psychedelic research are privileged, white, cisgender individuals (and Alexander believes they are using the privilege for good) But it's important for the psychedelic community to be vocal about privilege and be inclusive of all types of people, all repressed groups Alexander thinks that we need to eliminate the male/female diad The typical structure for psychedelic therapy is to have a male cisgender therapist and a female cisgender therapist But Alexander thinks this is gender essentializing Its totalizing of gender, assuming that the masculinity is held by the male therapist, and femininity is held by the female therapist Alexander thinks that the therapists should be more gender neutral Its essential to assess the individual needs of the client for specific gender pairing Recommendations Alexander's Reccomendations Confront Structural Heterosexism and Transfobia Retire the Male/Female Therapy Diad Acknowledgement in the Psychedelic world of the stress that LGBTQ people face We need to be able to run moderation analyses to see if a type of psychedelic treatment works the same for sexual minority populations as it does for straight folks Are there unique clinical considerations for sexual minorities? The psychedelic Renaissance is maturing and reaching a point where our approaches can be more inclusive He thinks it's important for straight folks to think about this too “We all suffer, including straight folks, in a world where the idea of gender and sexuality is firmly printed as either being A or B. It's a disservice to our identities.” - Alexander It is common to feel “oneness” after a psychedelic experience, and it's common for gender roles to change throughout the process And on the flip side, maybe our perception of other people’s gender (homophobia) transforms from a psychedelic experience, and we can become more accepting of other forms of gender Mystical Experience When people score higher on the mystical experience questionnaire (profound unity, transcendence of time and space) its predictive of their improvements on depression and anxiety It's important to be mindful of what value we put on marginalized people’s psychedelic experiences The most common issue Alexander sees is people feeling ‘stuck’ in these bodies Psychedelic medicine encourages (at least in appeal) embodiment Final Thoughts First, we need to come to terms with our own internalized homophobia, transphobia and racism Together, we learn from each other, how to dismantle types of patriarchal, homophibic and transphobic structures MDMA expanded access may probably end up being very expensive, we need to think about privilege and access to mental healthcare broadly It's not just about diversity, Alexander encourages people to create allies He has hope that we can proceed with integrity in these topics Links Alexander's website Center for Breakthroughs About Dr. Alexander Belser Alexander Belser, Ph.D., is a Clinical Research Fellow and clinical supervisor at Yale University. He is the Co-Investigator of two studies at Yale exploring psychedelic-assisted psychotherapy to treat OCD and depression. His research with sexual minority people has focused on preventing suicide among adolescents and on the protective role of gay-straight alliances for students. Dr. Belser was a founding member of the Psychedelic Research Group at NYU in 2006, and he is currently an Adjunct Faculty member in NYU’s graduate program in Counseling Psychology. He has been a researcher on various psychedelic studies of depression, anxiety, OCD, addiction, trauma, and among religious leaders. He is a study therapist for the MAPS study of MDMA-assisted psychotherapy for PTSD. Dr. Belser serves as a peer reviewer and has published peer-reviewed articles on topics such as psychedelic mysticism, altruism, patient experiences in psilocybin-assisted psychotherapy, cancer and psychedelic therapy, case studies, psilocybin treatment and posttraumatic growth (forthcoming).

Dr. Robin Carhart-Harris heads the Psychedelic Research Group within the Centre for Psychiatry at Imperial College London. He joins us on Adventures Through The Mind to talk about the Entropic Brain (and mind) theory, complexity vs. order, the disproportionate representation of 'ego' consciousness in modern civilisation and its impact on the natural world, confirmation biases and misreporting in psychedelic science and, of course, how psychedelics work in the brain. ---- Head to http://bit.ly/ATTMind93 for video, complete show notes, and relevant links. Head to the ATTMindPodcast subreddit to discuss this episode: https://www.reddit.com/r/ATTMindPodcast --- ------------------------------------- Support The Channel

This is a bonus episode deviating from our usual format. It is a short documentary exploring the work of the Psychedelic Research Group, who we interviewed back in episode 4, and a collective called Senscapes who create music and art from their neuroimaging data.  In the piece you'll hear from the Psychedelic Research Group, Senscapes, and an anonymous patient who participated in a clinical trial exploring the use of psilocybin as a treatment for depression. Woven into the interviews is the music created by Senscapes, aimed at taking listeners along on the patient journey.  If you plan to take a psychedelic in the near future, please see the Psychedelic Research Group’s survey at PsychedelicSurvey.com, and head over to Senscapes.com to find out more about their projects and upcoming performances. If you'd like to get in touch, our Gmail is "wonderlabspod". Enjoy!

Chris Timmermann is a researcher at Imperial College London’s Psychedelic Research Group, working under supervisors David Nutt and Robin Carhart-Harris. In this episode we look at the historical use of DMT across cultures, and what brain imaging studies reveal about brain activity during the psychedelic experience. We also dive into consciousness and the link of psychedelic experiences to meditation. If you'd like to get in touch, our Gmail is "wonderlabspod". Enjoy!

Dr. Rosalind Watts is a clinical psychologist at the Psychedelic Research Group at Imperial College London.The Psychedelic Research Group focuses on two main areas: first, the action of psychedelic drugs in the brain and second, their clinical utility, e.g. as aides to psychotherapy, with a particular focus on depression.The YC podcast is hosted by Craig Cannon.

This is Entheogen. Elevate the Conversation.Please support Entheogen by making a donation on Patreon. Become a Patron for as little as $1. Pledge just $3 or more, and get early access to new episodes, plus exclusive Patron-only features. Head over to EntheogenShow.com and click on Support.Find the notes and links for this and other episodes at EntheogenShow.com. Sign up to receive an email when we release a new episode. Follow us @EntheogenShow on Twitter and like EntheogenShow on FaceBook. Thanks for listening.It’s April 2, 2017, and we are talking with Dr. Rosalind Watts, Clinical Psychologist at Imperial College London, working alongside Dr. Robin Carhart-Harris.Joe’s story of psilocybin on his first “date” with his now-wife, and psilocybin’s role in their engagementThe Couples Using Magic Mushrooms as Relationship TherapyKevin’s regular practice of taking psychedelic medicine with his wifeHow Ros came to study psychedelic therapy after initially becoming disillusioned with the limits of talk therapy for the treatment of anxiety and depression; her initial skepticism about psychedelics based on their negative legacyThe importance of the patient-therapist relationshipSome guidelines from one of the father figures of psychedelic therapy, Bill Richards: “We prepare people to welcome whatever they may encounter – no picking and choosing. Sometimes you have to go through the dark night to get to the top of the mountain and the sunrise. If the inner dragon or monster appears, look him in the eye – go straight towards him. If you look the monster in the eye and go towards it, ask it what it wants – there’s always resolution, transformation, and new knowledge. When you run from it, you get into panic and paranoia, like a typical nightmare – and then you say, ‘I’ve had a bad trip.’”Although psychedelics including psilocybin tend to be considered non-addictive, there are examples of people using them habituallyRos mentions some examples of people in the psilocybin study for depression giving up addictions and habitual behaviorTo help fund this important research, visit the Psychedelic Research Group at Imperial College London

Chris Timmerman is a PhD student in the Psychedelic Research Group from Imperial College in London. He's currently conducting brain imaging experiments on people under the influence of the psychedelic drug DMT. In this episode, we talk about the psychedelics in general, ego dissolutionment and DMT. You can support this podcast at www.patreon.com/talkoftoday or at www.talkoftoday.com/support Support this podcastSupport this podcast at — https://redcircle.com/talk-of-today/donations